Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Important Milestone for Certain Japanese Patients With Uncontrolled LDL CholesterolFirst Approval for Amgen and Astellas Joint Venture
Amgen - Investors - RSS Content
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.